THE ONLY PH1 TREATMENT
PROVEN TO REDUCE
OXALATE LEVELS
ACROSS ALL AGE
AND STAGES
OF KIDNEY FUNCTION*†1-5
OXLUMO® (lumasiran) is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in children and adults. OXLUMO acts at the liver, the site of oxalate production. Overproduction of oxalate is the primary cause of disease manifestation in PH1.1,3-5
In clinical trials, OXLUMO was evaluated in both pediatric (including infants) and adult patients, including those with an estimated glomerular filtration rate (eGFR) ranging from 8.6 mL/min/1.73 m2 to ≥90 mL/min/1.73 m2 and patients on hemodialysis.1,6
OXLUMO’s effects on urinary and plasma oxalate levels were measured in clinical trials.1
Tell Me About OXLUMO Tell Me About PH1
Person with PH1
Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
WHY OXLUMO?
Natalie* Person with PH1
Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
OXLUMO is clinically proven to reduce oxalate levels1,5,7,8
It was studied in 3 separate clinical trials, which together included patients across all age groups and all stages of kidney function.†1,6
In clinical trials, OXLUMO was studied in infants, children, and adults with different stages of kidney disease from near normal (not on hemodialysis) up to advanced kidney disease, including patients on hemodialysis.1,6
OXLUMO is a targeted RNA interference (RNAi) therapeutic1,3
OXLUMO is an RNAi therapeutic that acts at the main site of oxalate production in the liver, targeting the HAO1 mRNA to decrease glycolate oxidase (GO) enzyme levels, which reduces the oxalate precursor.
HAO1=hydroxyacid oxidase 1; mRNA=messenger RNA.
Grace‡ Person with PH1
Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
OXLUMO is administered with flexibility
Depending on their insurance, patients can receive OXLUMO at home or in the office. A subcutaneous injection dosed by weight, OXLUMO is given quarterly for patients ≥10 kg or monthly for those <10 kg, after 4 initial monthly doses.1
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Alnylam Assist® provides support services for patients throughout their treatment with OXLUMO
Alnylam Assist® includes patient services in 4 key areas, including understanding insurance benefits and financial assistance options for eligible patients,* helping ensure access to therapy, and providing PH1 disease education.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
1. OXLUMO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc. 2. RIVFLOZA Prescribing Information. Plainsboro, NJ: Dicerna Pharmaceuticals, Inc. 3. Garrelfs SF, Frishberg Y, Hulton SA, et al. N Engl J Med. 2021;384(13):1216-1226. 4. Sas DJ, Magen D, Hayes W, et al. Genet Med. 2022;24(3):654-662. 5. Sellier-Leclerc A-L, Magen D, Shasha-Lavsky H, et al. Am J Kidney Dis. 2025;86(2):285-288. 6. Michael M, Groothoff JW, Shasha-Lavsky H, et al. Am J Kidney Dis. 2023;81(2):145-155.e1. 7. Saland JM, Lieske JC, Willey R, et al. Presented at: ASN Kidney Week; October 24-27, 2024; San Diego, CA. 8. Frishberg Y, Hayes W, Ben-Shalom E, et al. Presented at: National Kidney Foundation (NKF) Congress; April 10-13, 2025; Boston, MA.